Voyageur Pharmaceuticals Ltd.
Financial Statements (IFRS) · Amounts in CAD
Income Statement
Balance Sheet
Cash Flow
| Line Item | FY 2024Nov 30, 2024 | FY 2023Nov 30, 2023 | FY 2022Nov 30, 2022 | FY 2021Nov 30, 2021 |
|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling General And Administration | 1.2M | 940,008 | 1.1M | 1.5M |
| General And Administrative Expense | 1.2M | 940,008 | 1.1M | 1.5M |
| Research And Development | 287,439 | 280,944 | 527,561 | 496,514 |
| Depreciation And Amortization In Income Statement | 1,570 | 2,185 | 2,908 | 2,246 |
| Other Operating Expenses | 184,444 | 123,242 | 146,905 | 77,213 |
| Operating Expense | 1.7M | 1.3M | 1.8M | 2.0M |
| Operating Income | -1.7M | -1.3M | -1.8M | -2.0M |
| EBIT | -1.7M | -1.4M | -1.8M | -2.0M |
| Interest Expense | 0.00 | 4,480 | 0.00 | 3,277 |
| Interest Expense Non Operating | 0.00 | 4,480 | 0.00 | 3,277 |
| Net Interest Income | 0.00 | -4,480 | 0.00 | -3,277 |
| Other Income Expense | -7,941 | -48,610 | -1,969 | -- |
| Special Income Charges | -7,941 | -48,610 | -1,969 | 0.00 |
| Pretax Income | -1.7M | -1.4M | -1.8M | -2.1M |
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing And Discontinued Operation | -1.7M | -1.4M | -1.8M | -2.1M |
| Net Income From Continuing Operation Net Minority Interest | -1.7M | -1.4M | -1.8M | -2.1M |
| Net Income Including Noncontrolling Interests | -1.7M | -1.4M | -1.8M | -2.1M |
| Net Income Common Stockholders | -1.7M | -1.4M | -1.8M | -2.1M |
| Net Income | -1.7M | -1.4M | -1.8M | -2.1M |
| EBITDA | -1.7M | -1.4M | -1.7M | -2.0M |
| Normalized EBITDA | -1.7M | -1.3M | -1.7M | -2.0M |
| Reconciled Depreciation | 1,570 | 2,185 | 9,210 | 8,225 |
| Basic EPS | -0.01 | -0.01 | -0.02 | -0.02 |
| Diluted EPS | -0.01 | -0.01 | -0.02 | -0.02 |
| Basic Average Shares | 137.6M | 130.5M | 107.8M | 94.7M |
| Diluted Average Shares | 137.6M | 130.5M | 107.8M | 94.7M |
| Total Unusual Items | -7,941 | -48,610 | -1,969 | 0.00 |
| Total Unusual Items Excluding Goodwill | -7,941 | -48,610 | -1,969 | 0.00 |
| Tax Rate For Calcs | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Income | -1.7M | -1.4M | -1.8M | -2.1M |
| Depreciation Amortization Depletion Income Statement | 1,570 | 2,185 | 2,908 | 2,246 |
| Depreciation Income Statement | 1,570 | 2,185 | 2,908 | 2,246 |
| Diluted NI Availto Com Stockholders | -1.7M | -1.4M | -1.8M | -2.1M |
| Gain On Sale Of Ppe | -- | 0.00 | -6,210 | 0.00 |
| Impairment Of Capital Assets | 7,941 | 48,610 | 0.00 | -- |
| Net Income Continuous Operations | -1.7M | -1.4M | -1.8M | -2.1M |
| Net Non Operating Interest Income Expense | 0.00 | -4,480 | 0.00 | -3,277 |
| Other Gand A | 466,405 | 376,158 | 511,186 | 415,147 |
| Other Special Charges | -- | -- | -4,241 | -- |
| Salaries And Wages | 759,441 | 563,850 | 563,365 | 1.1M |
| Total Expenses | 1.7M | 1.3M | 1.8M | 2.0M |
| Line Item | FY 2024Nov 30, 2024 | FY 2023Nov 30, 2023 | FY 2022Nov 30, 2022 | FY 2021Nov 30, 2021 |
|---|---|---|---|---|
| Cash And Cash Equivalents | 165,569 | 2,085 | 31,561 | 812,967 |
| Cash Cash Equivalents And Short Term Investments | 165,569 | 2,085 | 31,561 | 812,967 |
| Accounts Receivable | 52,068 | 35,939 | 23,889 | 41,543 |
| Receivables | 52,068 | 35,939 | 23,889 | 41,543 |
| Inventory | 66,824 | 10,323 | 10,323 | 9,713 |
| Prepaid Assets | 74,164 | 40,283 | 91,407 | 23,099 |
| Current Assets | 358,625 | 88,630 | 157,180 | 887,322 |
| Gross PPE | 2.2M | 2.1M | 1.9M | 1.7M |
| Accumulated Depreciation | -14,046 | -12,476 | -10,291 | -54,624 |
| Net PPE | 2.2M | 2.1M | 1.9M | 1.7M |
| Other Non Current Assets | 14,000 | 14,000 | 14,000 | 14,000 |
| Total Non Current Assets | 2.2M | 2.1M | 1.9M | 1.7M |
| Total Assets | 2.6M | 2.2M | 2.1M | 2.6M |
| Current Debt And Capital Lease Obligation | -- | -- | -- | 16,557 |
| Accounts Payable | -- | -- | 591,306 | 584,660 |
| Payables | -- | -- | 591,306 | 604,559 |
| Payables And Accrued Expenses | 1.9M | 673,877 | 591,306 | 604,559 |
| Other Current Liabilities | 167,000 | -- | -- | 1.00 |
| Current Liabilities | 2.1M | 673,877 | 591,306 | 621,116 |
| Long Term Debt | 40,000 | 40,000 | 25,520 | 25,520 |
| Long Term Debt And Capital Lease Obligation | 40,000 | 40,000 | 25,520 | 25,520 |
| Long Term Capital Lease Obligation | -- | -- | -- | 0.00 |
| Other Non Current Liabilities | -- | -- | -- | 1.00 |
| Total Non Current Liabilities Net Minority Interest | 54,000 | 54,000 | 39,520 | 39,521 |
| Total Liabilities Net Minority Interest | 2.1M | 727,877 | 630,826 | 660,637 |
| Common Stock | 9.1M | 8.7M | 7.6M | 6.3M |
| Capital Stock | 9.1M | 8.7M | 7.6M | 6.3M |
| Additional Paid In Capital | 2.1M | 1.9M | 1.6M | 1.5M |
| Retained Earnings | -10.8M | -9.1M | -7.7M | -6.0M |
| Gains Losses Not Affecting Retained Earnings | 20,931 | 11,642 | 0.00 | -- |
| Other Equity Adjustments | 20,931 | 11,642 | -- | -- |
| Common Stock Equity | 449,958 | 1.4M | 1.5M | 1.9M |
| Stockholders Equity | 449,958 | 1.4M | 1.5M | 1.9M |
| Total Equity Gross Minority Interest | 449,958 | 1.4M | 1.5M | 1.9M |
| Total Capitalization | 489,958 | 1.5M | 1.5M | 1.9M |
| Net Tangible Assets | 449,958 | 1.4M | 1.5M | 1.9M |
| Tangible Book Value | 449,958 | 1.4M | 1.5M | 1.9M |
| Working Capital | -1.7M | -585,247 | -434,126 | 266,206 |
| Invested Capital | 489,958 | 1.5M | 1.5M | 1.9M |
| Total Debt | 40,000 | 40,000 | 25,520 | 42,077 |
| Net Debt | -- | 37,915 | -- | -- |
| Share Issued | 139.5M | 132.7M | 115.4M | 101.8M |
| Ordinary Shares Number | 139.5M | 132.7M | 115.4M | 101.8M |
| Capital Lease Obligations | -- | -- | 0.00 | 16,557 |
| Current Capital Lease Obligation | -- | -- | 0.00 | 16,557 |
| Dueto Related Parties Current | -- | -- | 0.00 | 19,899 |
| Finished Goods | 63,199 | 0.00 | -- | -- |
| Long Term Provisions | 14,000 | 14,000 | 14,000 | 14,000 |
| Other Properties | 2.2M | 2.1M | 1.9M | 1.7M |
| Raw Materials | 3,625 | 10,323 | -- | -- |
| Line Item | FY 2024Nov 30, 2024 | FY 2023Nov 30, 2023 | FY 2022Nov 30, 2022 | FY 2021Nov 30, 2021 |
|---|---|---|---|---|
| Operating Cash Flow | -302,289 | -991,252 | -1.7M | -1.6M |
| Cash Flow From Continuing Operating Activities | -302,289 | -991,252 | -1.7M | -1.6M |
| Depreciation And Amortization | 1,570 | 2,185 | 9,210 | 8,225 |
| Depreciation Amortization Depletion | 1,570 | 2,185 | 9,210 | 8,225 |
| Stock Based Compensation | 467,443 | 234,028 | 207,291 | 737,600 |
| Change In Working Capital | 926,983 | 110,151 | -243,725 | -342,664 |
| Changes In Account Receivables | -- | -- | 17,654 | 0.00 |
| Change In Receivables | -16,129 | -12,050 | 17,654 | -28,877 |
| Change In Inventory | -56,501 | 0.00 | -610.00 | 168.00 |
| Change In Payables And Accrued Expense | 1.0M | 71,077 | -192,461 | -290,856 |
| Change In Payable | -- | -- | -192,458 | -81,877 |
| Change In Other Current Liabilities | -- | -- | -- | -208,979 |
| Other Non Cash Items | -- | 14,480 | 56,154 | -1.00 |
| Net PPE Purchase And Sale | -- | 0.00 | 8,763 | 0.00 |
| Investing Cash Flow | -165,955 | -174,721 | -274,150 | -438,057 |
| Cash Flow From Continuing Investing Activities | -165,955 | -174,721 | -274,150 | -438,057 |
| Repayment Of Debt | -- | 0.00 | -16,557 | -18,853 |
| Net Issuance Payments Of Debt | -- | 0.00 | -16,557 | -18,853 |
| Issuance Of Capital Stock | 655,500 | 1.2M | 1.2M | 2.3M |
| Net Common Stock Issuance | 655,500 | 1.2M | 1.2M | 2.3M |
| Financing Cash Flow | 631,728 | 1.1M | 1.2M | 2.9M |
| Cash Flow From Continuing Financing Activities | 631,728 | 1.1M | 1.2M | 2.9M |
| Changes In Cash | 163,484 | -29,476 | -781,406 | 810,000 |
| Beginning Cash Position | 2,085 | 31,561 | 812,967 | 2,967 |
| End Cash Position | 165,569 | 2,085 | 31,561 | 812,967 |
| Free Cash Flow | -302,289 | -991,252 | -1.7M | -1.6M |
| Asset Impairment Charge | 7,941 | 48,610 | 0.00 | -- |
| Change In Account Payable | -- | -- | -192,458 | -81,877 |
| Change In Accrued Expense | -- | -- | 0.00 | -208,979 |
| Change In Interest Payable | -- | -- | 0.00 | -208,979 |
| Change In Prepaid Assets | -33,881 | 51,124 | -68,308 | -23,099 |
| Common Stock Issuance | 655,500 | 1.2M | 1.2M | 2.3M |
| Depreciation | 1,570 | 2,185 | 9,210 | 8,225 |
| Long Term Debt Payments | -- | 0.00 | -16,557 | -18,853 |
| Net Foreign Currency Exchange Gain Loss | 1,014 | -1,237 | -- | -- |
| Net Income From Continuing Operations | -1.7M | -1.4M | -1.8M | -2.1M |
| Net Long Term Debt Issuance | -- | 0.00 | -16,557 | -18,853 |
| Net Other Financing Charges | -28,876 | -63,452 | -59,004 | -175,970 |
| Net Other Investing Changes | -165,955 | -174,721 | -282,913 | -438,057 |
| Operating Gains Losses | 1,014 | -1,237 | 6,210 | -- |
| Proceeds From Stock Option Exercised | 5,104 | 0.00 | 41,000 | 786,116 |
| Sale Of PPE | -- | 0.00 | 8,763 | 0.00 |